Beam Therapeutics Inc. (BEAM)
Beam Therapeutics is a biotech firm using 'base editing' technology to rewrite DNA and potentially cure genetic diseases at their source.
Is Beam Therapeutics Inc. a good stock for a UK beginner?
The honest version: Beam Therapeutics is a biotech firm using 'base editing' technology to rewrite DNA and potentially cure genetic diseases at their source.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
The technology becomes a standard platform for treating multiple genetic diseases.
The technology proves too difficult or expensive to scale for patients.
What does Beam Therapeutics Inc. do?
Think of Beam as a genetic word processor; instead of just cutting DNA like older methods, they aim to precisely edit individual letters in the genetic code to fix errors. They make money through research partnerships with big pharmaceutical companies, though they are currently spending far more on research than they bring in from these deals. Everything rides on whether their clinical trials can show this complex technology is safe and effective in humans.
On our factor screen it looks strongest on growth and value, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 325% over the year
- ✓Low debt - a sturdier balance sheet
- Growth screens high (99/100)
- Pioneering 'base editing' technology with high potential
- Strong revenue growth from strategic partnerships
- Significant intellectual property portfolio
- Quality screens low (24/100)
- Income screens low (16/100)
- Clinical trials may fail to meet safety or effectiveness standards
- Regulatory bodies could block or delay new treatments
- Rapidly evolving competition in the gene-editing space
What do Beam Therapeutics Inc.'s numbers mean?
How much money does Beam Therapeutics Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Beam Therapeutics Inc. pay a dividend?
No - Beam Therapeutics Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does Beam Therapeutics Inc. report earnings, and how did recent quarters go?
Beam Therapeutics Inc. is next scheduled to report on about 2026-08-04 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-05-07 | $-1.01 | $-0.91 | Beat +10% |
| 2026-02-24 | $-1.12 | $2.33 | Beat +309% |
| 2025-11-04 | $-1.01 | $-1.10 | Missed -9% |
| 2025-08-05 | $-1.09 | $-1.00 | Beat +8% |
| 2025-05-06 | $-1.17 | $-1.24 | Missed -6% |
| 2025-02-25 | $-1.22 | $-1.09 | Beat +10% |
Across the last 6 quarters here, Beam Therapeutics Inc. came in ahead of what analysts expected 4 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Beam Therapeutics Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Beam Therapeutics Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Pioneering 'base editing' technology with high potential
- Strong revenue growth from strategic partnerships
- Significant intellectual property portfolio
- Currently losing money on every pound of revenue
- High reliance on external funding to keep research going
- Very high share price volatility
- Clinical trials may fail to meet safety or effectiveness standards
- Regulatory bodies could block or delay new treatments
- Rapidly evolving competition in the gene-editing space
The write-up's own warning lights — if these start happening, the case above changes.
- A permanent halt to clinical trials due to safety issues
- The company running out of cash without a new funding source
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.